Ivarmacitinib, a highly selective Janus kinase 1 (JAK1) inhibitor, tamed ankylosing spondylitis with sustained efficacy through 24 weeks in a phase 2/3 trial. A phase 2/3 trial in China evaluated the ...

Ankylosing spondylitis can be a devastating disease. But the good news is that the future is brighter than ever before. Here’s why I’m so optimistic. Doctors -- including primary care physicians -- ...

Ankylosing spondylitis is a type of arthritis that inflames joints of the spine and leaves your back stiff and painful. If nonsteroidal anti-inflammatory drugs (NSAIDs) aren't enough to relieve your ...

U ntil recently, the treatments for ankylosing spondylitis — a chronic, inflammatory type of arthritis that primarily affects the spine — have lagged behind those of other forms of arthritis. Luckily, ...